Description
SWOT ANALYSIS OF NOVO NORDISK
Novo Nordisk
Parent Company
Novo Nordisk
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Changing diabetes
It is leading healthcare company with experience in diabetes treatment USP & considerable experience in other area also
STP
Segment
Diabetes, homeostasis management & hormone replacement therapy
Endocrinologists, healthcare professionals providing treatment to Target Group patients suffering from diabetes & other hormonal disorders
Novo Nordisk is leading healthcare company with more than 89 years Positioning of experience in diabetes treatment.
SWOT Analysis
1. Deep knowledge about diabetes & experience in its treatment 2. Free cash flow can be used for expansion, acquisition or R&D 3. Around 33,000 well trained employees in 75 countries 4. Wide global footprint (present in 190 countries) 5. great diversity in senior management teams which is requisite for growth Strength 6. It was awarded as the most sustainable company in the world
1. Company suffered negative brand image due to its failure to provide information about side effects of Victoza. Weakness 2. Past legal actions have created negative image for company
1. Increasing prevalence of diabetes & other chronic ailments due to increasing urbanization & average life expectancy 2. Biosimiler market has strong growth opportunities Opportunity 3. Growing numbers of health conscious people
1. Increasing public debt in European countries 2. Negative consequences of healthcare reforms in major markets 3. Stringent healthcare regulations 4. Increasing pressure in public spending on healthcare due to Threats economic slowdown
Competition
1. Eli lily 2. AstraZeneca 3. Biocon Competitors 4. Abbott Laboratories
doc_401808104.docx
SWOT ANALYSIS OF NOVO NORDISK
Novo Nordisk
Parent Company
Novo Nordisk
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Changing diabetes
It is leading healthcare company with experience in diabetes treatment USP & considerable experience in other area also
STP
Segment
Diabetes, homeostasis management & hormone replacement therapy
Endocrinologists, healthcare professionals providing treatment to Target Group patients suffering from diabetes & other hormonal disorders
Novo Nordisk is leading healthcare company with more than 89 years Positioning of experience in diabetes treatment.
SWOT Analysis
1. Deep knowledge about diabetes & experience in its treatment 2. Free cash flow can be used for expansion, acquisition or R&D 3. Around 33,000 well trained employees in 75 countries 4. Wide global footprint (present in 190 countries) 5. great diversity in senior management teams which is requisite for growth Strength 6. It was awarded as the most sustainable company in the world
1. Company suffered negative brand image due to its failure to provide information about side effects of Victoza. Weakness 2. Past legal actions have created negative image for company
1. Increasing prevalence of diabetes & other chronic ailments due to increasing urbanization & average life expectancy 2. Biosimiler market has strong growth opportunities Opportunity 3. Growing numbers of health conscious people
1. Increasing public debt in European countries 2. Negative consequences of healthcare reforms in major markets 3. Stringent healthcare regulations 4. Increasing pressure in public spending on healthcare due to Threats economic slowdown
Competition
1. Eli lily 2. AstraZeneca 3. Biocon Competitors 4. Abbott Laboratories
doc_401808104.docx